Sectra includes CAD capabilities from iCAD in its mammography offering

Sectra includes CAD capabilities from iCAD in its mammography offering

The IT and medical-technology company Sectra has signed a distribution agreement
with iCAD, Inc., an industry-leading provider of computer-aided detection (CAD)
software products for the early identification of breast cancer. Sectra will
sell and support iCAD's products as part of its digital mammography solution.

iCAD will apply its patented detection algorithms to automatically identify and
clearly mark suspicious areas on mammograms from Sectra's digital mammography
system, Sectra MicroDose Mammography. The combination of Sectra's and iCAD's
products will deliver maximum diagnostic sensitivity and optimal performance to
enhance patient care.

“iCAD's digital CAD product complements our offering within mammography. By
offering such highly specialized software applications seamlessly integrated
into our products, we help our customers maximize the benefits of digital
technology”, says Jesper Söderqvist, Managing Director of Sectra's product
division for mammography.

Computer-Aided Detection - the radiologist's second pair of eyes
Computer-Aided Detection (CAD) is used by an increasing number of radiologists
as "a second pair of eyes" when reading mammograms. Analogous to a spellchecker
system on a personal computer, this technology uses detection algorithms to
identify areas on the mammogram containing characteristics that warrant a second
review by the radiologist. 

“We will optimize the performance of our powerful SecondLook detection
algorithms for Sectra's unique photon-counting technology to help increase usage
of CAD throughout Europe. Seamless integration of these two products will enable
radiologists to provide better clinical results faster - improving diagnostic
accuracy and clinical workflow.” says Ken Ferry, President and CEO of iCAD.

Using sophisticated algorithms, iCAD detection software enables earlier cancer
detection which improves survival rates and allows less invasive and more
effective treatment options.  iCAD's algorithms have been shown to detect up to
72% of actionable missed cancers at an average of 15 months earlier than
mammography alone. Optimized for Sectra's photon-counting technology, iCAD
algorithms identify patterns and use sophisticated mathematical analysis based
upon artificial intelligence to mark suspicious areas.


Dr. Torbjörn Kronander, President, Sectra Imtec AB, +46 705 23 52 27 
Dr. Jan-Olof Brüer, CEO and President, Sectra AB, +46 13 23 52 09


About Sectra's medical operations
Sectra is one of the world's major diagnostic imaging system (PACS) providers.
More than 900 hospitals worldwide use the system daily and more than 40 million
radiology examinations are diagnosed in Sectra's system annually. Sectra's
systems have been installed in North America, Scandinavia and most major
countries in Europe and the Far East. In Scandinavia, Sectra is the market
leader with more than 50% of all film-free installations.

About the Sectra Group
Sectra successfully develops and sells cutting-edge products in the expansive
niche segments of medical systems and secure communication systems. The company
was founded in 1978 and has its roots in the Linköping Institute of Technology
in Sweden. Today, Sectra has offices in eleven countries and operates through
partners worldwide. Sales in the 2005/2006 fiscal year totaled SEK 564 million.
Since 1999, the Sectra share is quoted on the Nordic Exchange. For more
information about Sectra visit http://www.sectra.com.

About iCAD, Inc. 
iCAD, Inc. (Nasdaq: ICAD) is an industry-leading provider of Computer-Aided
Detection (CAD) solutions that enable healthcare professionals to better serve
patients by identifying pathologies and pinpointing cancer earlier. iCAD offers
a comprehensive range of high-performance, upgradeable CAD systems for the high,
mid and low volume mammography markets. iCAD is entrusted with the task of early
cancer detection by almost one thousand women's healthcare centers worldwide.
For more information, visit www.icadmed.com